Table 2.

Risk factors for infective endocarditis in patients with incident ESRD receiving RRT in Denmark

ParameterNumber of EventsUnadjusted Incidence Rate/100,000 person-yearsHazard Ratio
(95% Confidence Interval)
Renal replacement modality
 Uncuffed CVC39305314.10 (7.76 to 25.50)
 Cuffed CVC39209910.03 (5.52 to 18.24)
 Arteriovenous fistula1388744.59 (2.73 to 7.73)
 Arteriovenous graft15703.19 (0.42 to 24.26)
 Unknown hemodialysis access248093.67 (1.94 to 6.94)
 Hemodialysis24110925.46 (3.28 to 9.10)
 Kidney transplant10850.41 (0.18 to 0.91)
 Peritoneal dialysis162121.00 (reference)
RRT periods
 RRT period 1a6713531.89 (1.37 to 2.60)
 RRT period 2a675010.80 (0.59 to 1.10)
 RRT period 3a1335491.00 (reference)
Sex
 Male1636070.91 (0.71 to 1.18)
 Female1046631.00 (reference)
Comorbidity
 Diabetes mellitus
  11028171.12 (0.87 to 1.45)
  01655491.00 (reference)
 Endocarditisb
  1201732122.24 (13.50 to 36.62)
  02475811.00 (reference)
Aortic valve disease
  14121392.65 (1.68 to 4.18)
  02265561.00 (reference)
Mitral valve disease
  12017571.38 (0.71 to 2.70)
  02475961.00 (reference)
  • Model adjusted for sex, age, diabetes, aortic valve disease, mitral valve disease, previous endocarditis, calendar year, renal replacement periods (<183, 184–845, and >845 d in RRT). CVC, central venous catheter.

  • a Renal replacement period 1: first 183 d in renal replacement period; renal replacement period 2: 184–845 d in renal replacement period; renal replacement period 3: >845 d.

  • b Before initiation of RRT.